Mast-Surgical-Error
Trivia for clinical trials: Leukemia CAR-T Trial

In July 2016, three adult leukemia patients died in a trial of a new cellular-level medicine by Juno Therapeutics. Nicknamed CAR-T, Juno’s new treatment option was supposed to attack the malignant cells until they appeared to have vanished. The technology was an up-and-coming phenomenon that many researchers called the “fifth pillar” of cancer treatment, but hopes were soon dashed by the results of the 2016 study.

241f95cad1c8a786436d5dd06909c93d71cf50ac 3trivia
Trivia for clinical trials: Leukemia CAR-T Trial

The cause of death for the three patients was swelling in the brain, medically known as cerebral edema. Representatives from the sponsoring medical company Juno admit that cerebral edema is rather common in patients who have been given CAR-T treatments, as are immune system reactions and increased neurological toxicity.

After the news of the deaths had been released, Juno’s stock fell 27 percent. Their practices are under FDA review, and it is unclear whether they will be allowed to continue their studies.

0 0 vote
Article Rating
Subscribe
Notify of
guest
2 评论
Inline Feedbacks
View all comments
AbcfPasegoabe
AbcfPasegoabe
2 months ago

CAR-T technology is a new cellular immunotherapy technology. Cellular immunotherapy is the use of immune cells for treatment. In the human body, it is lymphocytes that can directly kill viruses, leukemia cells, cancer cells, etc. Among them, the lymphocytes that are mainly responsible for killing viruses are called effector T lymphocytes. However, there are very few effector T lymphocytes in the body that can kill leukemia cells and cancer cells.

KuikCland
KuikCland
2 months ago

This disease costs a lot of money!